Some Experts Express Concern over Vaccine Approval Process in India
2021-01-16
LRC
TXT
大字
小字
滚动
全页
1Several groups representing scientists and doctors have expressed concerns over India's vaccine approval process.
2The concerns come after India approved a vaccine by Indian drugmaker Bharat Biotech.
3The vaccine was approved for emergency use on January 3, before it had completed late clinical trials.
4Late clinical trial data gives evidence about how effective a vaccine is in preventing illness from coronavirus infections.
5Many scientists have warned that approving a vaccine without evidence from late trials is risky.
6And a lack of clarity in the approval process could lead many people to delay getting the vaccine or to refuse to get it at all.
7More than 10.4 million coronavirus cases have been reported among India's nearly 1.4 billion people.
8Bharat Biotech's vaccine was one of two that India approved for emergency use.
9The second was a form of the AstraZeneca vaccine.
10It is made by the world's largest vaccine manufacturer, Serum Institute of India.
11Serum Institute's vaccine was approved because of partial results from studies in Britain and Brazil that showed it was about 70 percent effective.
12At first, a member of India's COVID-19 task force said the Bharat Biotech vaccine would be used as a "backup."
13Backup is a term that means something can be used to replace or support another person or thing.
14But on January 5, health officials said Bharat Biotech's vaccine would be made available to people who give their permission.
15People given the vaccine will also need to get follow-up visits.
16The move suggests India will send out both vaccines.
17But it remains unclear which states will receive which vaccine and for what reasons.
18On January 16, India will begin giving vaccines to an estimated 30 million doctors, nurses and other front line workers.
19After that, the shots will start going to around 270 million Indians who are either over age 50 or have other health issues, sometimes called "co-morbidities."
20China and Russia have also released vaccines while late clinical trials were still going on.
21But India, which is the world's largest manufacturer of vaccines, has drawn criticism for not being clear in its approval process and for using two different standards.
22A standard is a level of quality that is considered acceptable.
23The group of experts that approved the vaccines met three times.
24In the first two meetings, on Dec. 30 and Jan. 1, they were not pleased with Bharat Biotech's application.
25They asked for more data on its ability to prevent illness from COVID-19, notes from the meeting show.
26The AstraZeneca vaccine, meanwhile, was approved on Jan. 1.
27Notes from the Jan. 2 meeting show that the company presented "updated data."
28But it is not clear what new evidence led the experts to change their minds.
29Dr. Vineeta Bal of India's National Institute of Immunology noted the need for transparent approvals that include data to confirm vaccine effectiveness.
30"This is a process that Indian government officials are themselves sabotaging," she said.
31India's top drug official would not comment on the issue.
32The identities of the experts that approved the vaccines have not been made public.
33Balram Bhargava heads the Indian Council of Medical Research.
34He said the "restricted use" of a vaccine on the basis of data from early clinical trials is legally possible in a pandemic.
35The group is a co-sponsor of the clinical trials.
36I'm John Russell.
1Several groups representing scientists and doctors have expressed concerns over India's vaccine approval process. 2The concerns come after India approved a vaccine by Indian drugmaker Bharat Biotech. The vaccine was approved for emergency use on January 3, before it had completed late clinical trials. 3Late clinical trial data gives evidence about how effective a vaccine is in preventing illness from coronavirus infections. 4Many scientists have warned that approving a vaccine without evidence from late trials is risky. And a lack of clarity in the approval process could lead many people to delay getting the vaccine or to refuse to get it at all. 5More than 10.4 million coronavirus cases have been reported among India's nearly 1.4 billion people. 6Two Vaccines 7Bharat Biotech's vaccine was one of two that India approved for emergency use. The second was a form of the AstraZeneca vaccine. It is made by the world's largest vaccine manufacturer, Serum Institute of India. Serum Institute's vaccine was approved because of partial results from studies in Britain and Brazil that showed it was about 70 percent effective. 8At first, a member of India's COVID-19 task force said the Bharat Biotech vaccine would be used as a "backup." 9Backup is a term that means something can be used to replace or support another person or thing. 10But on January 5, health officials said Bharat Biotech's vaccine would be made available to people who give their permission. People given the vaccine will also need to get follow-up visits. 11The move suggests India will send out both vaccines. But it remains unclear which states will receive which vaccine and for what reasons. 12On January 16, India will begin giving vaccines to an estimated 30 million doctors, nurses and other front line workers. 13After that, the shots will start going to around 270 million Indians who are either over age 50 or have other health issues, sometimes called "co-morbidities." 14China and Russia have also released vaccines while late clinical trials were still going on. But India, which is the world's largest manufacturer of vaccines, has drawn criticism for not being clear in its approval process and for using two different standards. A standard is a level of quality that is considered acceptable. 15The group of experts that approved the vaccines met three times. In the first two meetings, on Dec. 30 and Jan. 1, they were not pleased with Bharat Biotech's application. They asked for more data on its ability to prevent illness from COVID-19, notes from the meeting show. The AstraZeneca vaccine, meanwhile, was approved on Jan. 1. 16Notes from the Jan. 2 meeting show that the company presented "updated data." But it is not clear what new evidence led the experts to change their minds. 17Dr. Vineeta Bal of India's National Institute of Immunology noted the need for transparent approvals that include data to confirm vaccine effectiveness. 18"This is a process that Indian government officials are themselves sabotaging," she said. 19India's top drug official would not comment on the issue. The identities of the experts that approved the vaccines have not been made public. 20Balram Bhargava heads the Indian Council of Medical Research. He said the "restricted use" of a vaccine on the basis of data from early clinical trials is legally possible in a pandemic. The group is a co-sponsor of the clinical trials. 21I'm John Russell. 22Aniruddha Ghosal and Sheikh Saaliq reported on this story for the Associated Press. John Russell adapted it for Learning English. Bryan Lynn was the editor. 23________________________________________________________________ 24Words in This Story 25clinical trial - n. a kind of research study in which human subjects are assigned to one or more treatments in order for researchers to study the effects of those treatments. 26task force - n. a group of people who deal with a specific problem 27application - n. an official request for something, usually made in writing 28update - v. give someone the most recent information 29transparent - adj. open an honest, without secrets 30sabotage - v. to destroy or damage (something) so that it does not work correctly 31sponsor - n. a person or organization that pays the cost of an activity or event 32We want to hear from you. Write to us in the Comments Section.